We tested whether SHP2 inhibition, predicted to block RAS-MAPK signaling and exert immunomodulatory effects, alters tumor volume or the immune microenvironment in PNFs, using flow cytometry and single-cell RNA sequencing. This evidence concerns the gene PTPN11 and neoplasm.